Download PDF
AJP Rep 2011; 01(01): 007-010
DOI: 10.1055/s-0030-1271217
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia

Mirjana Lulic-Botica
2   Pharmacy Department, Hutzel Women's Hospital, Wayne State University, Detroit, Michigan
,
Lilia DeJesus
1   Division of Neonatal/Perinatal Medicine, Wayne State University, Detroit, Michigan
3   Ann and Carman Adams Department of Pediatrics, Wayne State University, Detroit, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
24 January 2011 (online)

Also available at
   Permissions and Reprints

Abstract

Multidrug-resistant pathogens are becoming more difficult to treat with significantly increasing infection rates. The lack of new antibiotics to combat these strains has led to the resurgence of older antibiotics. This case highlights the first reported use of colistimethate sodium treatment in a 23-week gestational-age neonate with multidrug-resistant Acinetobacter baumannii pneumonia who developed acute renal failure and seizures shortly after initiation of treatment.

Keywords

Colistimethate - neonate - extremely low-birth-weight - multidrug resistant
 

  • References

  • 1 Wareham DW, Bean DC, Khanna P , et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27: 607-612
    CrossrefPubMedGoogle Scholar
  • 2 Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009; 69: 1879-1901
    CrossrefPubMedGoogle Scholar
  • 3 Li J, Nation RL, Turnidge JD , et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601
    CrossrefPubMedGoogle Scholar
  • 4 Touati A, Achour W, Cherif A , et al. Outbreak of Acinetobacter baumannii in a neonatal intensive care unit: antimicrobial susceptibility and genotyping analysis. Ann Epidemiol 2009; 19: 372-378
    CrossrefPubMedGoogle Scholar
  • 5 Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006; 64: 7-15
    CrossrefPubMedGoogle Scholar
  • 6 Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25: 596-599
    CrossrefPubMedGoogle Scholar
  • 7 Choi JY, Park YS, Kim CO , et al. Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J 2005; 35: 599-603
    CrossrefPubMedGoogle Scholar
  • 8 Chen LF, Kaye D. Current use for old antibacterial agents: polymyxins, rifamycins, and aminoglycosides. Infect Dis Clin North Am 2009; 23: 1053-1075, x
    CrossrefPubMedGoogle Scholar
  • 9 Motaouakkil S, Charra B, Hachimi A , et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-278
    CrossrefPubMedGoogle Scholar
  • 10 Iosifidis E, Antachopoulos C, Ioannidou M , et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010; 169: 867-874
    CrossrefPubMedGoogle Scholar
  • 11 Montero M, Horcajada JP, Sorlí L , et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009; 37: 461-465
    CrossrefPubMedGoogle Scholar
  • 12 Hartzell JD, Neff R, Ake J , et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-1728
    CrossrefPubMedGoogle Scholar
  • 13 Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-868
    CrossrefPubMedGoogle Scholar
  • 14 Santamaría C, Mykietiuk A, Temporiti E, Stryjewski ME, Herrera F, Bonvehi P. Nephrotoxicity associated with the use of intravenous colistin. Scand J Infect Dis 2009; 41: 767-769
    CrossrefPubMedGoogle Scholar
  • 15 Naranjo CA, Busto U, Sellers EM , et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
    CrossrefPubMedGoogle Scholar
  • 16 Simmonds A, Munoz J, Aguero-Rosenfeld M , et al. Outbreak of Acinetobacter infection in extremely low birth weight neonates. Pediatr Infect Dis J 2009; 28: 210-214
    PubMedGoogle Scholar